1101 related articles for article (PubMed ID: 9519339)
1. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
Chapman MJ; Guérin M; Bruckert E
Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
[TBL] [Abstract][Full Text] [Related]
2. [Role of anomalies of low density lipoproteins (LDL) in atherogenicity].
Chapman JM; Guérin M; Bruckert E
Bull Acad Natl Med; 2001; 185(1):35-7; discussion 38-9. PubMed ID: 11474567
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
5. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
6. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
7. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.
Lamarche B; Lemieux I; Després JP
Diabetes Metab; 1999 Sep; 25(3):199-211. PubMed ID: 10499189
[TBL] [Abstract][Full Text] [Related]
8. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
9. Overview of fenofibrate.
Packard CJ
Eur Heart J; 1998 Feb; 19 Suppl A():A62-5. PubMed ID: 9519345
[TBL] [Abstract][Full Text] [Related]
10. [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
Zeman M; Zák A; Tvrzická E; Konárková M; Stípek S
Cas Lek Cesk; 2002 Apr; 141(7):211-6. PubMed ID: 12053756
[TBL] [Abstract][Full Text] [Related]
11. PPAR agonists in the treatment of insulin resistance and associated arterial disease.
Camejo G
Int J Clin Pract Suppl; 2003 Mar; (134):36-44. PubMed ID: 12793596
[TBL] [Abstract][Full Text] [Related]
12. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects.
Griffin BA; Minihane AM; Furlonger N; Chapman C; Murphy M; Williams D; Wright JJ; Williams CM
Clin Sci (Lond); 1999 Sep; 97(3):269-76. PubMed ID: 10464051
[TBL] [Abstract][Full Text] [Related]
13. Diabetic dyslipidaemia.
Erkelens DW
Eur Heart J; 1998 Jul; 19 Suppl H():H27-40. PubMed ID: 9717062
[TBL] [Abstract][Full Text] [Related]
14. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
15. Lipid modification in type 2 diabetes: the role of LDL and HDL.
Vergès B
Fundam Clin Pharmacol; 2009 Dec; 23(6):681-5. PubMed ID: 19650852
[TBL] [Abstract][Full Text] [Related]
16. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
Kontush A; Chapman MJ
Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
[TBL] [Abstract][Full Text] [Related]
17. Management of hypercholesterolaemia in the patient with diabetes.
Packard C; Olsson AG
Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
[TBL] [Abstract][Full Text] [Related]
18. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
Mertens A; Verhamme P; Bielicki JK; Phillips MC; Quarck R; Verreth W; Stengel D; Ninio E; Navab M; Mackness B; Mackness M; Holvoet P
Circulation; 2003 Apr; 107(12):1640-6. PubMed ID: 12668499
[TBL] [Abstract][Full Text] [Related]
19. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
[TBL] [Abstract][Full Text] [Related]
20. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
Watts GF; Ji J; Chan DC; Ooi EM; Johnson AG; Rye KA; Barrett PH
Clin Sci (Lond); 2006 Sep; 111(3):193-9. PubMed ID: 16700661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
